Molecule Details
| InChIKey | BAINIUMDFURPJM-UHFFFAOYSA-N |
|---|---|
| Compound Name | Oxatomide |
| Canonical SMILES | O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 6.64 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB12877 |
|---|---|
| Drug Name | Oxatomide |
| CAS Number | 60607-34-3 |
| Groups | approved |
| ATC Codes | R06AE06 |
| Description | Oxatomide has been used in trials studying the treatment of Muscular Dystrophy, Duchenne. |
Categories: Anti-Allergic Agents Anti-Asthmatic Agents Antihistamines for Systemic Use Histamine Agents Histamine Antagonists Histamine H1 Antagonists Moderate Risk QTc-Prolonging Agents Neurotransmitter Agents Piperazine Derivatives QTc Prolonging Agents Respiratory System Agents
Cross-references: BindingDB: 76863 ChEBI: 31943 CHEMBL13828 ChemSpider: 4454 D01773 PharmGKB: PA163522137 PubChem:4615 PubChem:347829033 RxCUI: 54236 Wikipedia: Oxatomide ZINC: ZINC000019632896
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P35367 | HRH1 | Histamine H1 receptor | antagonist | targets |